Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care, Surgical and Sports Medicine markets, today announced the completion of its previously announced business combination between Organogenesis Inc. and Avista Healthcare Public Acquisition Corp. The transaction was approved by AHPAC’s shareholders at an extraordinary general meeting, and by Organogenesis Inc.’s stockholders at a special meeting, each held on December 10, 2018.
As previously reported, affiliates of Avista Capital Partners, a leading private equity firm, have invested a total of $92 million in the combined company in conjunction with the business combination.
ORGO has applied to continue the listing of ORGO Class A common stock and ORGO public warrants on the NASDAQ under the proposed symbols “ORGO” and “ORGOW” respectively.
Organogenesis’ management team, led by Gary S. Gillheeney, Sr., will run the combined company.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We are pleased to have closed this transaction with Organogenesis and look forward to a very successful partnership,” said Thompson Dean, Managing Partner and Co-CEO of Avista. “Organogenesis is an ideal partner for Avista, given its leading position in the rapidly accelerating regenerative medicine sector, numerous growth opportunities and demonstrated ability to execute on product development and commercialization capabilities. Collectively, we will work to create tremendous value for Organogenesis’ patients, investors, employees and key stakeholders.”
Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis, said, “We are delighted to have completed this transaction and look forward to capitalizing on Tom Dean and Avista’s strategic expertise as Organogenesis uses the capital from this investment to execute on its compelling growth objectives and continues to deliver its customers a versatile product portfolio to substantially improve the lives of their patients.”
Credit Suisse Securities LLC acted as financial advisor to AHPAC. Weil, Gotshal & Manges LLP acted as legal advisor to AHPAC. Foley Hoag LLP acted as legal advisor to Organogenesis.
Date: December 17, 2018
Source: Yahoo Finance
